BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

28 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

07 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

09 1 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 1 2023 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant

10 12 2022 10:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

02 12 2022 14:00:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

02 12 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

30 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

14 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming Investor Conferences

09 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

07 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting

03 11 2022 09:01:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection

19 9 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference

01 9 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

09 8 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

02 8 2022 08:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

27 6 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

03 6 2022 06:42:39 提供 Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results

09 5 2022 06:30:00 提供 Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming May Investor Conferences

04 5 2022 06:30:00 提供 Nasdaq GlobeNewswire